[Prophylactic use of tranexamic acid in noncardiac surgery : Update 2017].
Avainsanat
Abstrakti
BACKGROUND
Minimising perioperative bleeding is a key goal of "patient blood management" programs. One component of respective strategies includes preventive inhibition of fibrinolysis using protease inhibitors, such as tranexamic acid (TXA). TXA inhibits plasminogen activation and plasmin-induced fibrin degradation.
OBJECTIVE
The present article provides an overview of the existing literature and TXA applications in the prophylaxis of perioperative bleeding.
METHODS
Literature search in PubMed/MEDLINE (U.S. National Library of Medicine®, Bethesda, MD, USA).
RESULTS
TXA reduces perioperative blood loss and transfusion requirements in several randomized controlled trials (RCTs) and meta-analyses in the field of hip and knee arthroplasty for both intravenous and topical use. Moreover, evidence favours use of TXA in complex spine surgery and reconstructive surgery (e. g. craniosynostosis in children). Single RCTs showed benefits of TXA in abdominal hysterectomy, open prostatectomy, liver surgery and actively bleeding trauma patients. For prophylaxis of peripartum haemorrhage (PPH) following vaginal delivery or Caesarean section, TXA cannot be routinely recommended, although evidence points to benefits in actively bleeding patients. A recommendation exists for the treatment of (active) PPH. For prophylactic perioperative administration, different dosage regimens exist for adults. Most often an initial i. v. bolus of 1 g or 10-15 mg/kg body weight with/without repetition after 6 h or continuous infusions over 8 h is administered. Increased rates of thromboembolic events were not noted.
CONCLUSIONS
Protease inhibitors such as TXA reduce perioperative blood loss and transfusion requirements in selected surgical fields.